Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 15/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196375 | 0.81 | PKM (0.46) | DUTPKMALDH1A1LMNAENPP1 | |
| SCHEMBL13057077 | 0.77 | FGFR1 (0.46) | LMNA | |
| SCHEMBL14391833 | 0.73 | PKM (0.41) | DUTPKMALDH1A1LMNAENPP1 | |
| SCHEMBL24372004 | 0.72 | DUT (0.35) | DUTPKMALDH1A1LMNA | |
| SCHEMBL18661677 | 0.72 | DUT (0.35) | DUTPKMALDH1A1LMNA | |
| SCHEMBL16503452 | 0.72 | DUT (0.39) | DUTPKMALDH1A1LMNAENPP1 | |
| SCHEMBL20599908 | 0.72 | PKM (0.57) | DUTPKMALDH1A1LMNAENPP1 | |
| SCHEMBL19171430 | 0.70 | PKM (0.52) | DUTPKMALDH1A1LMNAL3MBTL1 | |
| SCHEMBL16576318 | 0.70 | PKM (0.40) | DUTPKMALDH1A1LMNAENPP1 | |
| SCHEMBL18636215 | 0.70 | POLB (0.35) | DUTPKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305060-A1 | Nucleoside Prodrugs and Uses Thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305060-A1 | Nucleoside Prodrugs and Uses Thereof | PNP, NUDT1, ENTPD5 | DUT 18/4885PKM 1807/4885ALDH1A1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.